Aptamer Group Plc (APTA) AI Stock Analysis

• Market Cap: £7.47M
• Dividend Yield: N/A
• Average Volume (3M): 9.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.32
• Revenue Growth: 17.39%
• EPS Growth: 96.02%
• Country: UK
• Employees: 28
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 1,991,343,000
• 10 Day Avg. Volume: 14,721,811
• 30 Day Avg. Volume: 9,692,502
• PEG Ratio: >-0.01
• Price to Book (P/B): 15.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: 0.50p ▲(31.58%Upside)

Aptamer Group Plc's overall stock score is primarily influenced by its challenging financial performance and valuation metrics. However, the positive technical indicators and numerous strategic corporate events provide a counterbalance, suggesting potential growth opportunities in a high-risk environment.

Aptamer Group Plc Business Overview & Revenue Model

Company Description

Aptamer Group Plc (APTA) is a biotechnology company specializing in the development and application of aptamer technology. The company operates within the life sciences sector, focusing on the discovery and development of aptamers, which are synthetic molecules that can bind to specific targets such as proteins, cells, and small molecules with high affinity and specificity. Aptamer Group provides custom aptamer discovery and development services for research, diagnostics, and therapeutic applications across various industries including pharmaceuticals, diagnostics, and bio-manufacturing.

How the Company Makes Money

Aptamer Group Plc generates revenue primarily through its custom aptamer discovery and development services. The company collaborates with pharmaceutical and biotechnology companies, offering tailored solutions for the identification and development of aptamers that meet specific client needs. These services are provided under contract research agreements, where clients pay for the discovery and development process. Additionally, Aptamer Group may license its aptamer technology to other companies, receiving licensing fees and potential milestone payments. The company's strategic partnerships and collaborations with industry leaders also contribute to its revenue streams, enabling joint development projects and expanding the commercial reach of its aptamer technologies.

Aptamer Group Plc Financial Statement Overview

Summary

Aptamer Group Plc faces significant financial challenges, with declining revenues and negative profit margins. The company relies on debt, with a debt-to-equity ratio of 0.92, and struggles with negative cash flows, indicating a need for improved cash management and operational efficiency.

Income Statement

Aptamer Group Plc's income statement shows significant challenges in maintaining revenue and profitability. The company has experienced declining revenues and negative profit margins, with a net profit margin of -343.02% and negative EBIT and EBITDA margins. Revenue has decreased by 50.91% compared to the previous year, reflecting a need to improve its revenue-generating strategies.

Balance Sheet

The balance sheet indicates a moderate level of risk with a debt-to-equity ratio of 0.92, showing reliance on debt financing. The equity ratio stands at 32.02%, which signals some stability. However, the return on equity is negative at -333.71%, highlighting inefficiencies in generating returns from equity.

Cash Flow

Cash flow analysis reveals substantial negative free cash flow, demonstrating cash management challenges. The operating cash flow to net income ratio is 0.77, indicating some alignment between operating cash flow and net income, though both are negative. The company needs to focus on improving cash flow generation.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Mar 2020
Income Statement
Total Revenue	1.22M	860.00K	1.75M	4.04M	1.28M	854.57K
Gross Profit	510.00K	250.00K	359.00K	2.69M	538.40K	455.97K
EBITDA	-2.17M	-2.81M	-7.36M	-2.19M	-2.24M	-733.59K
Net Income	-2.26M	-2.96M	-7.84M	-2.09M	-1.85M	-674.73K
Balance Sheet
Total Assets	4.35M	2.77M	2.75M	11.52M	2.06M	1.39M
Cash, Cash Equivalents and Short-Term Investments	1.97M	870.00K	234.00K	6.69M	369.00K	293.15K
Total Debt	643.00K	817.00K	69.00K	1.31M	78.00K	160.98K
Total Liabilities	1.78M	1.88M	2.45M	3.47M	1.96M	1.14M
Stockholders Equity	2.56M	887.00K	304.00K	8.05M	105.00K	245.81K
Cash Flow
Free Cash Flow	-1.87M	-2.41M	-6.09M	-2.79M	-1.26M	-243.54K
Operating Cash Flow	-1.85M	-2.28M	-4.06M	-2.38M	-1.10M	-82.71K
Investing Cash Flow	-116.00K	-122.00K	-2.03M	-418.00K	-339.20K	-160.79K
Financing Cash Flow	2.18M	3.04M	-365.00K	9.12M	1.50M	-190.51K

Aptamer Group Plc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Positive. The current price of 0.38 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.35, and above the 200-day MA of 0.32, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 60.67 is Neutral, neither overbought nor oversold. The STOCH value of 48.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:APTA.

Aptamer Group Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APTA	54 Neutral	£7.47M	―	-99.43%	―	17.39%	96.02%
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
OBD	44 Neutral	£5.09M	―	-333.59%	―	45.22%	―
FAB	44 Neutral	£7.33M	―	-129.49%	―	14.12%	78.16%

Aptamer Group Plc Corporate Events

Aptamer Group Raises £2 Million to Boost Optimer® Technology Commercialization

Aptamer Group plc has raised £2.0 million through a placing of ordinary shares to accelerate the commercialization of its Optimer® technology and strengthen its market position. The funds will support manufacturing investments, enhance licensing negotiations, and launch new services, including biomarker discovery and AI-driven aptamer development. This capital raise is expected to boost the company’s credibility, improve supply chain reliability, and open new opportunities in the life sciences sector, positioning Aptamer as a global leader in aptamer technology.

Aptamer Group Advances Liver Fibrosis Treatment with Optimer® Breakthrough

Aptamer Group plc has announced a significant breakthrough in its liver fibrosis treatment program using its Optimer® platform. The company has identified a novel molecular target that enhances the platform’s potential to deliver targeted gene therapy to liver cells responsible for scarring. This advancement positions Aptamer for strategic licensing discussions with pharmaceutical partners, addressing a critical unmet need in the $20 billion fibrosis market. The Optimer® platform, acting like a ‘magic bullet’, targets scarred liver cells to deliver siRNA, potentially reducing or reversing fibrosis. Laboratory tests have shown promising results, and Aptamer is planning in vivo studies to further evaluate the platform’s efficacy and safety, paving the way for human trials and strategic collaborations.

Aptamer Group Enters Strategic Partnership to Develop Optimer®-Fc Reagent

Aptamer Group plc has entered into a development and licensing agreement with a major global life sciences company to create a custom Optimer®-Fc reagent for immunohistochemistry assays and diagnostic kits. This partnership, which includes a royalty structure, is expected to enhance Aptamer’s recurring revenue potential and expand the application of its Optimer platform in high-value life sciences markets, highlighting the commercial potential and technical capabilities of its technology.

Aptamer Group Expands Collaboration with Unilever for New Odour Control Solutions

Aptamer Group plc has signed a second development agreement with Unilever to create a new panel of Optimer binders targeting body odour pathways. This collaboration, which follows a successful initial programme, positions Aptamer to expand its presence in the personal care sector, leveraging Unilever’s significant market share and the projected growth of the deodorant market.

Aptamer Group Unveils Promising Data on Optimer Platform for Fibrotic Diseases

Aptamer Group plc has announced new data on its Optimer therapeutic delivery vehicle, which shows promise for treating liver fibrosis and other fibrotic conditions. Presented at the ASGCT Annual Meeting, the data highlights the platform’s adaptability and potential for broad therapeutic application, positioning it as a significant player in the multi-billion-dollar market for fibrotic disease treatments. The collaboration with AstraZeneca and interest from multiple pharmaceutical companies suggest strong future commercial opportunities.

Aptamer Group Secures New Contracts and Licensing Agreements, Boosting Growth

Aptamer Group plc has announced two new development contracts with existing customers, valued at up to £231,000, highlighting the growing commercial traction of its Optimer platform. The company has also entered into licensing agreements with a global enzyme provider, which include milestone payments and royalties, further expanding its revenue streams and reinforcing its strategic focus on sustainable growth. These agreements reflect Aptamer’s increasing influence in the life sciences sector and its commitment to long-term value creation.

Aptamer Group Advances Alzheimer’s Test with New ELISA Format and Royalty Agreement

Aptamer Group plc has successfully adapted its Optimer-based Alzheimer’s disease test into an ELISA format, enhancing its potential for commercialization in hospital laboratories. The company has also secured a royalty agreement with Neuro-Bio Ltd, allowing it to receive royalties on sales of the diagnostic test. This development is part of a strategic effort to capitalize on the $8.3 billion Alzheimer’s diagnostic market, which is expected to grow significantly. The new test format, which uses non-invasive saliva sampling, promises to improve accessibility and speed up diagnosis, potentially transforming the market by addressing a major unmet clinical need.

Aptamer Group Enters Licensing Deal for Swine Vaccine Adjuvants

Aptamer Group plc has entered a global licensing agreement with the University of Glasgow to commercialize Optimer binders as vaccine adjuvants in the swine health sector. This partnership allows Aptamer to tap into the $1.75 billion global swine vaccine market, with the University leading product development and commercialization expected within 12 months. Aptamer will earn a 10% royalty on sales, creating a scalable revenue stream and reinforcing its strategy to leverage its proprietary platform across multiple verticals.

Aptamer Group Unveils Breakthrough in Targeted Gene Therapy for Liver Fibrosis

Aptamer Group plc announced its presentation of new data on the Optimer® delivery vehicle at the 2025 ASGCT Annual Meeting. The data highlights the vehicle’s precision-targeting capabilities for fibrotic liver disease, addressing critical barriers in RNAi drug development by enabling targeted delivery of RNAi therapies to activated hepatic stellate cells. This advancement could enhance therapeutic efficacy, reduce off-target effects, and expand the clinical utility of gene therapies, marking a significant step forward in the treatment of chronic diseases.